quinazolines has been researched along with Pruritus in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furue, M; Kadono, T; Nakahara, T; Tsuji, G | 1 |
| Chu, CY; Hauschild, A; Lacouture, ME; O'Brien, D; Schadendorf, D; Stammberger, U; Uttenreuther-Fischer, M | 1 |
| Kishi, A; Kiyohara, Y; Yamazaki, N | 1 |
| Andoh, T; Kuraishi, Y; Yoshida, T | 1 |
| Ishii, N; Shirato, M; Wakita, H | 1 |
| Andoh, T; Kuraishi, Y | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Del Giudice, P; Delord, JP; Hubiche, T; Roché, H; Sibaud, V; Tournier, E | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Biaoxue, R; Hua, L; Shuanying, Y; Wenlong, G | 1 |
| Santini, D; Tonini, G; Vincenzi, B | 1 |
| Levêque, D | 1 |
| Buhren, BA; Gerber, PA; Homey, B | 1 |
| Blanchet, B; Goldwasser, F; Mir, O | 1 |
| Chu, DT; Guan, ZZ; Jiang, GL; Li, LY; Li, W; Liu, XY; Zhang, L; Zhao, HY | 1 |
| Calarese, P; Morse, L | 1 |
| Gerdes, S; Mrowietz, U | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Okamoto, Y; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Bae, EA; Cai, XF; Kim, DH; Lee, JJ; Shin, YW | 1 |
| Chen, XQ; Rong, TH; Wei, WD; Wen, ZS; Wu, HY | 1 |
| Kardaun, SH; van Duinen, KF | 1 |
| Loffeld, A; Orpin, SD; Talsania, N | 1 |
6 review(s) available for quinazolines and Pruritus
| Article | Year |
|---|---|
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Topics: Administration, Topical; Adult; Animals; Antipruritics; Child; Dermatitis, Atopic; Humans; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Pruritus; Quinazolines | 2017 |
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.
Topics: Administration, Oral; Afatinib; Alopecia; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Exanthema; Humans; Paronychia; Protein Kinase Inhibitors; Pruritus; Quinazolines; Receptor, ErbB-2 | 2013 |
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines | 2013 |
Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Hand-Foot Syndrome; Humans; Lapatinib; Neoplasms; Pruritus; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2016 |
EGFR-targeted therapy and related skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Humans; Ichthyosis; Middle Aged; Neoplasms; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pruritus; Quinazolines; Signal Transduction; Skin Care; Trastuzumab | 2006 |
3 trial(s) available for quinazolines and Pruritus
| Article | Year |
|---|---|
[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quinazolines; Survival Rate | 2005 |
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pruritus; Quinazolines; Treatment Outcome | 2006 |
[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quality of Life; Quinazolines; Remission Induction | 2007 |
13 other study(ies) available for quinazolines and Pruritus
| Article | Year |
|---|---|
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Topics: Animals; Antipruritics; Cyclic AMP; Dermatitis, Atopic; Disease Models, Animal; Inflammation; Male; Mice; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Pruritus; Quinazolines; Signal Transduction; Skin | 2014 |
Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
Topics: Animals; Dermatitis, Atopic; Disease Models, Animal; Humans; Mice; Nerve Growth Factor; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Pruritus; Quinazolines | 2014 |
Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Administration, Topical; Animals; Antipruritics; Cells, Cultured; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Injections, Intradermal; Keratinocytes; Leukotriene B4; Male; Mice; Mice, Inbred ICR; Oligopeptides; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Pruritus; Quinazolines; Receptor, PAR-2; Skin; Tryptases | 2014 |
Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.
Topics: Adult; Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Quinazolines; Skin Diseases, Papulosquamous; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Aprepitant for erlotinib-induced pruritus.
Topics: Adult; Aged; Aprepitant; Erlotinib Hydrochloride; Female; Humans; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2010 |
Aprepitant for erlotinib-induced pruritus.
Topics: Antineoplastic Agents; Aprepitant; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2010 |
More on aprepitant for erlotinib-induced pruritus.
Topics: Antiemetics; Aprepitant; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines; Substance P | 2011 |
More on aprepitant for erlotinib-induced pruritus.
Topics: Adenocarcinoma; Aprepitant; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2011 |
Follicular rash during therapy with erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Facial Dermatoses; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2006 |
In vitro and in vivo antiallergic effect of the fructus of Evodia rutaecarpa and its constituents.
Topics: Alkaloids; Animals; Anti-Allergic Agents; Behavior, Animal; Cell Degranulation; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Evodia; Fruit; Indole Alkaloids; Interleukin-4; Male; Mast Cells; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; p-Methoxy-N-methylphenethylamine; Passive Cutaneous Anaphylaxis; Plant Extracts; Pruritus; Quinazolines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2007 |
Erlotinib-induced florid acneiform rash complicated by extensive impetiginization.
Topics: Aged; Anti-Bacterial Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Eruptions; Emollients; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Minocycline; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2008 |
Colloidal oatmeal lotion is an effective treatment for pruritus caused by erlotinib.
Topics: Avena; Colloids; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Phytotherapy; Plant Preparations; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2008 |